Literature DB >> 15095041

Portal and peripheral cortisol levels in obese humans.

W Aldhahi1, E Mun, A B Goldfine.   

Abstract

AIMS/HYPOTHESIS: Excess total body and visceral fat has been associated with insulin resistance, diabetes and the metabolic syndrome. Excess glucocorticoids produce both central obesity and diabetes. However, systemic glucocorticoid levels are normal in typical Type 2 diabetes and persons with idiopathic obesity. Glucocorticoids can be produced locally through the enzyme 11 beta hydroxysteroid dehydrogenase type 1 (11 beta HSD-1). Transgenic mice with selective overexpression in adipose tissue of 11 beta HSD-1 to levels seen in humans develop visceral obesity, hyperlipidaemia and insulin-resistant diabetes associated with a 2.7-fold increase in corticosterone levels in portal compared to peripheral circulation. To examine whether the liver is exposed to higher levels of glucocorticoids, which may undergo metabolic degradation prior to measurement in the systemic circulation, we assessed concentrations of cortisol in the portal and peripheral circulation in morbidly obese humans.
METHODS: Portal and peripheral blood samples were obtained simultaneously from six morbidly obese humans with and without diabetes during bariatric abdominal surgery. The samples were assessed for serum cortisol to determine whether an increase in the portal to peripheral circulation is found in obese humans. Insulin, which undergoes metabolic clearance in the liver, and thyroxin (free T(4)), which does not, were also assessed.
RESULTS: Levels of serum cortisol (698.8+/-200.4 vs 696.3+/-232.4 nmol/l, portal vs peripheral, p=0.9) and free T(4) (22.0+/-7.8 vs 20.6+/-8.1 pmol/l, portal vs peripheral, p=0.3) were not significantly different in portal compared to peripheral circulation. Portal insulins were significantly higher than peripheral levels (466.7+/-302.9 vs 78.5+/-50.9 pmol/l, portal vs peripheral, p=0.03). CONCLUSIONS/
INTERPRETATION: These observations suggest that in morbidly obese humans the liver is not exposed to excess glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095041     DOI: 10.1007/s00125-004-1389-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  18 in total

1.  Does central obesity reflect "Cushing's disease of the omentum"?

Authors:  I J Bujalska; S Kumar; P M Stewart
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

2.  Cortisol secretion in relation to body fat distribution in obese premenopausal women.

Authors:  P Mårin; N Darin; T Amemiya; B Andersson; S Jern; P Björntorp
Journal:  Metabolism       Date:  1992-08       Impact factor: 8.694

3.  Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.

Authors:  M Homma; A Tanaka; K Hino; H Takamura; T Hirano; K Oka; M Kanazawa; T Miwa; Y Notoya; T Niitsuma; T Hayashi
Journal:  Metabolism       Date:  2001-07       Impact factor: 8.694

4.  Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.

Authors:  N M Morton; M C Holmes; C Fiévet; B Staels; A Tailleux; J J Mullins; J R Seckl
Journal:  J Biol Chem       Date:  2001-08-23       Impact factor: 5.157

Review 5.  Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome.

Authors:  B L Wajchenberg; D Giannella-Neto; M E da Silva; R F Santos
Journal:  Horm Metab Res       Date:  2002 Nov-Dec       Impact factor: 2.936

Review 6.  Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.

Authors:  Hiroaki Masuzaki; Jeffrey S Flier
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2003-12

7.  Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation.

Authors:  B R Walker; A A Connacher; R M Lindsay; D J Webb; C R Edwards
Journal:  J Clin Endocrinol Metab       Date:  1995-11       Impact factor: 5.958

8.  Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians.

Authors:  Robert S Lindsay; Deborah J Wake; Saraswathy Nair; Joy Bunt; Dawn E W Livingstone; Paska A Permana; P Antonio Tataranni; Brian R Walker
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

9.  Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium.

Authors:  H Hauner; G Entenmann; M Wabitsch; D Gaillard; G Ailhaud; R Negrel; E F Pfeiffer
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

10.  Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior.

Authors:  R P Eaton; R C Allen; D S Schade; K M Erickson; J Standefer
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

View more
  6 in total

Review 1.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 2.  Is "Cushing's disease of the omentum" an affliction of mouse and men?

Authors:  B R Walker
Journal:  Diabetologia       Date:  2004-04-17       Impact factor: 10.122

3.  Translating PUFA omega 6:3 ratios from wild to captive hibernators (Urocitellus parryii) enhances sex-dependent mass-gain without increasing physiological stress indicators.

Authors:  Monica Mikes; Sarah A Rice; Doug Bibus; Alexander Kitaysky; Kelly L Drew
Journal:  J Comp Physiol B       Date:  2022-05-03       Impact factor: 2.230

Review 4.  Hypercortisolism in obesity-associated hypertension.

Authors:  Amy G Varughese; Oksana Nimkevych; Gabriel I Uwaifo
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

5.  Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.

Authors:  Roland H Stimson; Jonas Andersson; Ruth Andrew; Doris N Redhead; Fredrik Karpe; Peter C Hayes; Tommy Olsson; Brian R Walker
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

6.  Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men.

Authors:  H B Holt; S H Wild; A D Postle; J Zhang; G Koster; M Umpleby; F Shojaee-Moradie; K Dewbury; P J Wood; D I Phillips; C D Byrne
Journal:  Diabetologia       Date:  2007-03-17       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.